Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 92.15 USD -0.45%
Market Cap: 114.8B USD
Have any thoughts about
Gilead Sciences Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one GILD stock under the Base Case scenario is 83.94 USD. Compared to the current market price of 92.15 USD, Gilead Sciences Inc is Overvalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GILD Relative Value
Base Case
83.94 USD
Overvaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.1
P/S
P/S
Price to Sales
4.1
vs History
1
vs Industry
72
Median 3Y
3.5
Median 5Y
3.3
Industry
7.6
Forward
4
More Details
915.4
P/E
P/E
Price to Earnings
915.4
vs History
1
vs Industry
1
Median 3Y
18.2
Median 5Y
17.8
Industry
22.1
Forward
20.6
More Details
11.5
P/OCF
P/OCF
Price to OCF
11.5
vs History
14
vs Industry
12
Median 3Y
10.6
Median 5Y
9.1
Industry
21.9
More Details
11.5
P/FCFE
P/FCFE
Price to FCFE
11.5
vs History
68
vs Industry
9
Median 3Y
13.2
Median 5Y
12.8
Industry
23.4
More Details
6.3
P/B
P/B
Price to Book Value
6.3
vs History
1
vs Industry
17
Median 3Y
4.5
Median 5Y
4.1
Industry
2.5
More Details
3.9
EV/S
EV/S
Enterprise Value to Sales
3.9
vs History
38
vs Industry
58
Median 3Y
3.9
Median 5Y
3.8
Industry
7.5
Forward
3.8
More Details
5
EV/GP
EV/GP
Enterprise Value to Gross Profit
5
vs History
33
vs Industry
54
Median 3Y
5
Median 5Y
4.7
Industry
9.3
More Details
10.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.2
vs History
25
vs Industry
10
Median 3Y
8.7
Median 5Y
8.7
Industry
4.2
Forward
11.9
More Details
10.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.2
vs History
55
vs Industry
8
Median 3Y
10.3
Median 5Y
10.5
Industry
4
Forward
13.1
More Details
11
EV/OCF
EV/OCF
Enterprise Value to OCF
11
vs History
46
vs Industry
10
Median 3Y
11.6
Median 5Y
10.6
Industry
5.9
More Details
11
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
11
vs History
50
vs Industry
8
Median 3Y
12.4
Median 5Y
11
Industry
3.9
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
9
vs Industry
46
Median 3Y
2
Median 5Y
2
Industry
4.5
More Details

Multiples Across Competitors

GILD Competitors Multiples
Gilead Sciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
35.8B EUR 19.2 -134.7 -108.8 -79.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.6B USD 15.1 -95.2 -226 -158.8
P/S Multiple
Revenue Growth P/S to Growth
US
Gilead Sciences Inc
NASDAQ:GILD
Average P/S: 3 457 241.3
4.1
10%
0.4
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.2
220%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.1
96%
0.2
P/E Multiple
Earnings Growth P/E to Growth
US
Gilead Sciences Inc
NASDAQ:GILD
Average P/E: 211.7
915.4
77%
11.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -134.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -95.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Gilead Sciences Inc
NASDAQ:GILD
Average EV/EBITDA: 16.2
10.2
16%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -226 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Gilead Sciences Inc
NASDAQ:GILD
Average EV/EBIT: 21.2
10.2
32%
0.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -158.8 N/A N/A

See Also

Summary
GILD intrinsic value, competitors valuation, and company profile.
DCF Valuation
GILD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GILD stock valuation using valuation multiples.
Wall Street Estimates
GILD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GILD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.